# The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

> **NCT01836198** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** LY2409021
- **DRUG:** Gemfibrozil
- **DRUG:** Ketoconazole
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT01836198
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836198, "The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01836198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*